Interim Report January - March 2026
(PR-inside.com) STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the first quarter 2026. "For the more than 300,000 people diagnosed with i…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


